In this study,
targeted nanomedicines made from polymeric building blocks that are utilized in numerous FDA approved products to date, were nanoengineered to carry an anti-inflammatory drug payload in the form of a biomimetic peptide.
Maastricht, The Netherlands, 1 November 2017 — Cristal Therapeutics, a clinical stage biopharmaceutical company developing
targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced today that it has begun a Phase 1b...
Passive
targeting nanomedicines are not enough to improve the drug accumulation at the tumor target site for the high hypovascularization level.
It is also the first example of using
targeted nanomedicine to reduce atherosclerosis in animals.
Not exact matches
«The siRNA delivery
targeted carriers constructed today hone in on specific cells and require chemical conjugation of the
targeting agent,» says Prof. Dan Peer of the Laboratory of Precision
Nanomedicine at TAU's School of Molecular Cell Biology and Biotechnology, who led the research.
Published in
Nanomedicine, the study identified a new mechanism of
targeting multi-subunit complexes that are critical to the function of viruses, bacteria or cancer, thus reducing or possibly even eliminating their resistance to
targeted drugs.
In their report that has received advance online publication in Nature Nanotechnology, a research team based at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) describes how a
nanomedicine that combines photodynamic therapy — the use of light to trigger a chemical reaction — with a molecular therapy drug
targeted against common treatment resistance pathways reduced a thousand-fold the dosage of the molecular therapy drug required to suppress tumor progression and metastatic outgrowth in an animal model.
In fact, the mice that received the complete
nanomedicine package had smaller tumors and longer lifespans than their counterparts injected with saline, nanoparticles without the drug, the drug alone, and nanoparticles with the drug but without the
targeting aptamers.
The way the
nanomedicines were designed enabled this biological therapeutic to be released at the
target site, the atherosclerotic plaque, in a controlled manner.
Nanomedicine: Swarming towards the
target, Nature Materials (2011).
Nanomedicines, for example, often encapsulate drugs in molecular packages decorated with segments of molecules that enable them to
target specific organs and diseases, and, once there, convince those cells to ingest the medication.